About us

Our strength is in our foundation...

Our foundations

• Strong cash position with sustainable revenues
• Targeting growing respiratory market with current sales $25 billion
• Late-stage pipeline approaching commercialisation
• Talented and motivated staff

"It has been a year that has provided good pipeline progress and opportunities for Vectura with both NVA237 and QVA149 in Phase III clinical development.

We re-acquired US rights from Sandoz for development of VR315 in March and will continue to move the development programme forward in a cost-effective manner whilst monitoring the regulatory framework and assessing third-party interest. Vectura retains the rights to the product outside the US and Europe which represents an important licensing opportunity.

The expansion and progression of our product pipeline has been undertaken while focusing on our financial goal of becoming a sustainably cash-generative business following receipt of substantial milestone and royalty revenues from our partnered late-stage respiratory programmes. In the short term, we will continue to manage cash carefully as we fund investment in our development activities from both current revenue streams and cash resources."

Dr Chris Blackwell Chief Executive of Vectura